301 related articles for article (PubMed ID: 24714754)
1. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
3. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Lee JL; Ahn JH; Choi MK; Kim Y; Hong SW; Lee KH; Jeong IG; Song C; Hong BS; Hong JH; Ahn H
Br J Cancer; 2014 May; 110(10):2472-8. PubMed ID: 24736579
[TBL] [Abstract][Full Text] [Related]
5. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
7. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
8. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
9. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG
Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515
[TBL] [Abstract][Full Text] [Related]
10. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
11. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
Serrate C; Loriot Y; De La Motte Rouge T; Gross-Goupil M; Massard C; Escudier B; Bossi A; Fizazi K
Ann Oncol; 2009 May; 20(5):965. PubMed ID: 19403938
[No Abstract] [Full Text] [Related]
12. The postchemotherapy PSA surge syndrome.
Thuret R; Massard C; Gross-Goupil M; Escudier B; Di Palma M; Bossi A; de Crevoisier R; Chauchereau A; Fizazi K
Ann Oncol; 2008 Jul; 19(7):1308-1311. PubMed ID: 18356135
[TBL] [Abstract][Full Text] [Related]
13. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Zhang HL; Yang LF; Zhu Y; Yao XD; Zhang SL; Dai B; Zhu YP; Shen YJ; Shi GH; Ye DW
Prostate; 2011 Feb; 71(3):326-31. PubMed ID: 20842666
[TBL] [Abstract][Full Text] [Related]
14. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
15. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
18. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
[TBL] [Abstract][Full Text] [Related]
19. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Italiano A; Ortholan C; Oudard S; Pouessel D; Gravis G; Beuzeboc P; Bompas E; Fléchon A; Joly F; Ferrero JM; Fizazi K
Eur Urol; 2009 Jun; 55(6):1368-75. PubMed ID: 18706755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]